Actively Recruiting
Phase I Study of OH2 Injection via Transcatheter Intraarterial Infusion for Safety and Pharmacokinetics in Advanced Liver Cancer Patients
Led by Binhui Biopharmaceutical Co., Ltd. · Updated on 2024-12-20
12
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating OH2 injection as a potential treatment for patients with advanced liver cancer, specifically hepatocellular carcinoma, in an open-label Phase I clinical trial. The study aims to assess the safety, tolerability, and how the drug behaves in the body when given through a transcatheter intraarterial infusion. This trial is sponsored by Binhui Biopharmaceutical Co., Ltd. and focuses on patients who have not responded to or are not suitable for standard treatments. Participants receive OH2 injection administered directly into the tumor via intratumoral injection once every three weeks. This dose-escalation study involves increasing doses to find the maximum tolerated dose over a period of two years. The treatment is delivered through a catheter placed in the artery supplying the liver tumor, allowing targeted drug infusion. During the trial, participants will be closely monitored for dose-limiting toxicities within the first three weeks after treatment begins and throughout the two-year study period. Researchers will evaluate adverse events, tumor response rates, disease control, survival, viral shedding, and immune responses. Participants will undergo laboratory tests, physical exams, and imaging assessments to track treatment effects and safety during and after the study.
CONDITIONS
Brief Title
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
Research Team
C
chuansheng zheng, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here